GIBSON DUNN

Gibson Dunn Advises Xoma Royalty on Acquisition of Royalty and Milestone Interest in Takeda’s Mezagitamab

Firm News | May 28, 2025

Gibson Dunn represented Xoma Royalty in connection with its acquisition from BioInvent International of its royalty and milestone interest in Takeda's mezagitamab for up to $30 million. In exchange for BioInvent's economic interest in mezagitamab, XOMA Royalty paid $20 million to BioInvent at closing and will pay an additional $10 million upon mezagitamab achieving regulatory approval in the IgA nephropathy indication from the FDA.

Mezagitamab is in a Phase 3 clinical trial for the treatment of patients with immune thrombocytopenia (ITP), a rare immune-mediated bleeding disorder.

Gibson Dunn regularly advises life sciences companies and investors on complex royalty and milestone transactions in the biopharmaceutical sector.

The Gibson Dunn corporate team included Todd Trattner, Ayushi Sutaria, and Natan Sebhat. Pamela Lawrence Endreny and Ryan Rott advised on tax.

Related Capabilities

Life Sciences

FDA and Health Care

Mergers and Acquisitions

Tax

Related People

Ayushi Sutaria

Pamela Lawrence Endreny

Ryan Rott

© 2026 Gibson, Dunn & Crutcher LLP. All rights reserved. For contact and other information, please visit us at www.gibsondunn.com. | **www.gibsondunn.com**